GSK raised its full-year guidance after second quarter core earnings rose 13%, helped by higher sales in oncology, HIV and its general medicines portfolio.
Related Posts
Battling for Budget Bookings, Discount Airlines Offer ‘Poor Man’s First Class’
Spirit and Frontier bundle amenities such as alcohol, Wi-Fi and bigger seats as they weather financial turbulence.
Financial Services Roundup: Market Talk
Find insight on Legal & General, IAG and more in the latest Market Talks covering Financial Services.